This is consistent with a large US cohort study of 123,752 matched patients on SGLT2 inhibitors and DPP4 inhibitors which also found a lower risk of UTI hospitalisations (HR 0.68; 95% CI 0.54, 0.87) [48]. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.